Blockchain Registration Transaction Record

Biotech's New Frontier: Science Becomes a Financial Asset Class

Biotech industry transforms as scientific progress becomes recognized financial asset. Oncotelic Therapeutics leads shift with fair-value accounting and $1B+ GMP Bio valuation. Learn how innovation drives new valuation models.

This transformation fundamentally changes how investors, companies, and the market value biotech innovation. For investors, it means more transparent and sophisticated valuation models that better reflect a company's true potential beyond traditional revenue metrics. For biotech companies, it provides new ways to demonstrate value to shareholders and secure funding based on scientific progress rather than just commercial products. This shift could accelerate drug development by creating more efficient capital allocation and potentially bringing promising therapies to market faster. The recognition of scientific progress as a financial asset represents a maturation of the biotech industry that could lead to more sustainable business models and greater investor confidence in a sector traditionally viewed as high-risk.